Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.
Multiple sclerosis and related disorders November 1, 2025 Yang Yang, Xinyi Duan, Jing Wang et al. 1 citation
Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatment of relapsing multiple sclerosis (RMS) in China up to data. Real-world data are necessary to investigate the factors for switching from oral DMTs and to assess the effectiveness and safety of ofatumumab in the Chinese MS population. We conducted a...
DOI: 10.1016/j.msard.2025.106827 (opens in new tab)
Full text (opens in new tab)
Multiple sclerosis
Ofatumumab
Real-world data
Switch
+2